Fluicell AB (FLUI) - Total Liabilities
Based on the latest financial reports, Fluicell AB (FLUI) has total liabilities worth Skr5.58 Million SEK (≈ $600.50K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Fluicell AB to assess how effectively this company generates cash.
Fluicell AB - Total Liabilities Trend (2014–2024)
This chart illustrates how Fluicell AB's total liabilities have evolved over time, based on quarterly financial data. Check FLUI cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Fluicell AB Competitors by Total Liabilities
The table below lists competitors of Fluicell AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Human Xtensions Ltd
TA:HUMX
|
Israel | ILA3.66 Million |
|
Downing Renewables & Infrastructure Trust PLC
LSE:DORE
|
UK | GBX1.79 Million |
|
Martello Technologies Group Inc
V:MTLO
|
Canada | CA$24.05 Million |
|
International Prospect Ventures Ltd
V:IZZ
|
Canada | CA$240.93K |
|
CPT GLOBAL LTD
F:714
|
Germany | €8.09 Million |
|
Luxbright AB
ST:LXB
|
Sweden | Skr12.49 Million |
|
CCSC Technology International Holdings Limited Ordinary Shares
NASDAQ:CCTG
|
USA | $675.92K |
|
Propanc Biopharma, Inc. Common Stock
NASDAQ:PPCB
|
USA | $4.66 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Fluicell AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Fluicell AB market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.18 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fluicell AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fluicell AB (2014–2024)
The table below shows the annual total liabilities of Fluicell AB from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr6.27 Million ≈ $675.18K |
-29.62% |
| 2023-12-31 | Skr8.91 Million ≈ $959.40K |
+7.15% |
| 2022-12-31 | Skr8.32 Million ≈ $895.36K |
+5.72% |
| 2021-12-31 | Skr7.87 Million ≈ $846.94K |
+47.60% |
| 2020-12-31 | Skr5.33 Million ≈ $573.81K |
-45.10% |
| 2019-12-31 | Skr9.71 Million ≈ $1.05 Million |
+273.54% |
| 2018-12-31 | Skr2.60 Million ≈ $279.80K |
+33.13% |
| 2017-12-31 | Skr1.95 Million ≈ $210.17K |
+109.10% |
| 2016-12-31 | Skr934.00K ≈ $100.51K |
-7.71% |
| 2015-12-31 | Skr1.01 Million ≈ $108.91K |
+108.76% |
| 2014-12-31 | Skr484.76K ≈ $52.17K |
-- |
About Fluicell AB
Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. The company offers BIOPEN, a microfluidic platform for high-precision single-cell solution delivery that enables to control the cell microenvironment without moving or disturbing the cells; Biozone 6 that generate dose-response curves or study the effects of mu… Read more